TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07465835: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Sponsor: Electra Therapeutics Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,057,976

Rescue Site Savings

+$3,330,096

Unlock Full NCT07465835 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07465835 Rescue Dossier →